Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for May 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during May 2014.

For an indepth analysis of these deals, read 'Pharma deals during May 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Merck & Co OTC Business / Bayer
Asset / product acquisition
Consumer care business incl. Claritin, Afrin and Coppertone brands
14,200
CFR Pharmaceuticals / Abbott
Company acquisition
Chile-based branded generic company with Latin America (2013 sales  $768m)
3,330
Bayer / Merck & Co
Co-development and co-commercialisationSoluble guanylate cyclase modulators for cardiovascular disease2,100
Valeant / Nestle
Asset / product acquisitionInjectable cosmetic fillers for facial wrinkles including Dysport1,400
Ophthotech / Novartis
Commercialisation1 and co-development licenceFovista (start p3) for treatment of wet age-related macular degeneration1,030
Chelsea / Lundbeck
Company acquisitionUS company with treatments for rare neurologic diseases658
Avalanche / Regeneron
Development and commercialisation licenceGene therapy products for ophthalmologic disease 653
Merck & Co / Santen
Asset / product acquisition2Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m600+
MacroGenics / Takeda
Option to license end p1a to develop and commercialise
MGD010, a preclinical bispecific antibody for treatment of auto-immune disease502
VersaPharm / Akorn
Company acquisitionUS generic company selling dermatology products with $100m sales440
Bayer Interventional Device Business / Boston Scientific 
Asset / product acquisitionDevices for coronary and peripheral vascular disease (2013 sales $120m)415
CytomX / BMS
Development and commercialisation licence
Selective monoclonal antibodies (“Probodies”) for up to 4 oncology targets348
Bedford Labs (Boehringer Ingelheim) / Hikma
Asset / product acquisitionUS generic injectable manufacturer and products (2013 sales $19m) 300
GSK product / Pernix
Asset / product acquisition3Marketed sumatriptan/naproxen combination. 2013 sales $79m267
Lumena / Shire
Company acquisition
US company with late stage compounds for treatment of rare GI / hepatic diseases260+
Xenoport / Reckitt Benckiser
Development and commercialisation licence
Arbaclofen placarbil end pIIa for alcohol use disorders145
Neurotez / GCA Therapeutics
Development and commercialisation licence4Leptin derivatives for treatment of cognitive disorders
103
Fibrotech / Shire
Company acquisition
Australian company with pIb product for rare fibrotic kidney disease
75+
Ligand / Omthera (AstraZeneca)
Research, development and commercialisation licence
Omthera's prodrug delivery platform for omega-3  fatty acids for dyslipidaemia 45
Viking / Ligand
Licence to develop. Ligand provides $2.5m loan

Five development small molecule programmes. Lead product pIIb type 2 diabetes
N/D
AntiOp / Reckitt Benckiser
Supply and marketing agreementIntranasal naloxone for opioid abuse in late clinical development
N/D

All deals are worldwide unless otherwise noted.
1 - Ex-US
2 - Japan and key markets in Europe and Asia Pacific
3 - US
4 - China

The Deal Watch table is compiled by Medius Associates

9th June 2014

The Deal Watch table is compiled by Medius Associates

9th June 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Infographics